BioArctic AB (LTS:0RV2) Beginning Cash Position: kr1,040 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RV2 BioArctic AB LTS:0RV2
75 GF Score
Price kr315.50
GF Value kr486.53
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is BioArctic AB Beginning Cash Position?

BioArctic AB LTS:0RV2 +1.28% 75 Beginning Cash Position is kr1,040 Mil as of Mar. 2026. GuruFocus rates LTS:0RV2 with a GF Score™ of 75/100 and a GF Value™ of kr486.53 (Significantly Undervalued). The stock has 2 warning signs investors should review.

BioArctic AB's Beginning Cash Position for the quarter that ended in Mar. 2026 was kr1,040 Mil.

BioArctic AB's quarterly Beginning Cash Position increased from Sep. 2025 (kr948 Mil) to Dec. 2025 (kr1,105 Mil) but then declined from Dec. 2025 (kr1,105 Mil) to Mar. 2026 (kr1,040 Mil).

BioArctic AB's annual Beginning Cash Position declined from Dec. 2023 (kr805 Mil) to Dec. 2024 (kr612 Mil) and declined from Dec. 2024 (kr612 Mil) to Dec. 2025 (kr513 Mil).

BioArctic AB Beginning Cash Position Related Terms

BioArctic AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for BioArctic AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioArctic AB Beginning Cash Position Chart

BioArctic AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 999.94 848.40 805.39 611.57 512.93

BioArctic AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 512.93 558.57 948.14 1,104.59 1,040.43
LTS:0RV2
75GF Score
BioArctic AB LTS:0RV2
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioArctic AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr1,040 Mil mean?
BioArctic AB (LTS:0RV2) has a Beginning Cash Position of kr1,040 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BioArctic AB and its competitors.
Is BioArctic AB's Beginning Cash Position too high?
BioArctic AB's current Beginning Cash Position is kr1,040 Mil. Overall, BioArctic AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Beginning Cash Position compare to VRTX and REGN?
BioArctic AB's Beginning Cash Position of kr1,040 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on BioArctic AB and its competitors. BioArctic AB's current Beginning Cash Position is kr1,040 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Significantly Undervalued. The stock's GF Value™ is kr486.53, compared to a current price of kr315.50 — trading 35.2% below its estimated fair value. The current Beginning Cash Position is kr1,040 Mil. BioArctic AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current Beginning Cash Position is kr1,040 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (LTS:0RV2) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of kr315.50 is trading 35.2% below its estimated GF Value™ of kr486.53. GuruFocus considers BioArctic AB to be Significantly Undervalued.

Key valuation signals for LTS:0RV2:

  • Beginning Cash Position: kr1,040 Mil
  • GF Value™: kr486.53 vs. price of kr315.50 (35.2% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
75GF Score

Get the complete analysis for LTS:0RV2

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr315.50
Price
kr486.53
GF Value